27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
A double blind, comparative, parallel and randomized clinical trial was used for evaluation of two nootropics with anti-aging actions: Meclofenoxate (MF) and Antagonic-Stress (AS). 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Introducción: La enfermedad de Alzheimer (EA) representa la causa más común de demencia a nivel mundial, caracterizada por un deterioro progresivo de la memoria y otras funciones cognitivas. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dürfen Medikamente mit minimaler Wirkung und im Einzelfall schweren Nebenwirkungen (auf die hier aus Platzgründen nicht weiter eingegangen wird), den PatientInnen, die sich ja auch große Hoffnungen machen, zugemutet werden? 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer-Perusini's disease (AD) represents a growing health crisis. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The approval of lecanemab and donanemab represents a watershed moment in Alzheimer Disease (AD) treatment, yet clinicians face a novel challenge: guiding patients through treatment selection when head-to-head comparative data are absent. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Yearly costs of evolocumab were $6,840. Donanemab was more expensive at $32,000. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
As of April 3, 2025, 944 HCPs (neurologists 14%, geriatricians 5%, primary care providers 25%) and 2,269 P/Cs engaged with the contents. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer’s disease (AD) is the most widespread neurodegenerative disorder and a leading cause of dementia seen in clinical practice. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The VHA is well-positioned to use a hybrid approach-both telehealth and in-person care-to support the provision of amyloid-targeting therapies for veterans with AD. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
controversias de los tratamientos de la enfermedad de Alzheimer» In response to 'Advances and controversies in the treatments of Alzheimer's disease' Sr. Editor, Felicitamos a la Dra.M. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
As a result of multiple phosphorylation, Tau undergoes early conformational changes involving the bending of the intact amino (N)-terminus over the third repeated domain, which in turn was evidenced by positive immunolabeling with the monoclonal antibody Alz-50 [2]. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Amyloid-related imaging abnormalities (ARIA) in the form of edema/effusions (ARIA-E) or hemorrhagic lesions (ARIA-H) are the most impactful adverse event associated with anti-amyloid immunotherapy for Alzheimer disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer disease (AD) is a major health issue of global concern whereby there are minimal treatment options. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease, AD, has been a difficult problem for relevant experts and patients since its discovery. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Lecanemab and Donanemab are two new FDA-approved antiamyloid immunotherapies that are Alzheimer disease modifying agents. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Canada’s Drug Agency (CDA-AMC) recommends that Leqembi be reimbursed by public drug plans for the treatment of adult patients in the early stages of Alzheimer disease (AD) (i.e., mild cognitive impairment [MCI] or mild dementia) who have evidence of amyloid in the brain and who are APOE epsilon 4 (APOE4) noncarriers or heterozygotes, if certain conditions are met. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
La carta al editor presenta recomendaciones actualizadas para el uso de donanemab en la enfermedad de Alzheimer (EA), basadas en su papel dentro de la hipótesis de la cascada amiloide. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Este ensayo tiene como objetivo analizar la eficacia del lecanemab como terapia modificadora de la enfermedad de Alzheimer (EA). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Anti-amyloid immunotherapy agents represent a novel and clinically significant class of humanized monoclonal antibodies designed to selectively bind and clear pathological amyloid-beta (Aβ) aggregates from the brain, thereby slowing the progression of early Alzheimer’s disease (AD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by memory loss, cognitive decline, and behavioral changes. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Mit der Einführung neuer Alzheimer-Therapien wie den Anti-Amyloid-Antikörpern Lecanemab und Donanemab rückt ein bislang wenig bekanntes, aber hochaktuelles Phänomen in den Fokus: ARIA – Amyloid-related Imaging Abnormalities. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Neue Alzheimer-Therapien mit Anti-Amyloid-Antikörpern wie Lecanemab oder Donanemab eröffnen Betroffenen neue Chancen – stellen die Radiologie jedoch vor besondere Herausforderungen. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer disease (AD) is no longer viewed only as a clinical syndrome of memory impairment but as a biological disease continuum driven by interacting amyloid-β, tau, glial, vascular, metabolic, and synaptic mechanisms. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer disease (AD) is a pathological worsening process of neurodegenerative disease characterised by impaired thinking, memory and behavioural problems, which have a considerable health impact worldwide. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Corticobasal syndrome (CBS) is a combination of extrapyramidal disorders (asymmetric parkinsonism, dystonia, myoclonia) and cortical disorders (apraxia, disorders of complex types of sensitivity, the alien limb phenomenon). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →